Type I interferons and SARS-CoV-2: from cells to organisms

Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro produce low levels of type I IFNs, and SARS-CoV-2 proteins can inhibit various steps in type I IFN production and response. Ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastard, Paul, Zhang, Qian, Zhang, Shen-Ying, Jouanguy, Emmanuelle, Casanova, Jean-Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786610/
https://www.ncbi.nlm.nih.gov/pubmed/35149239
http://dx.doi.org/10.1016/j.coi.2022.01.003
_version_ 1784639148889473024
author Bastard, Paul
Zhang, Qian
Zhang, Shen-Ying
Jouanguy, Emmanuelle
Casanova, Jean-Laurent
author_facet Bastard, Paul
Zhang, Qian
Zhang, Shen-Ying
Jouanguy, Emmanuelle
Casanova, Jean-Laurent
author_sort Bastard, Paul
collection PubMed
description Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro produce low levels of type I IFNs, and SARS-CoV-2 proteins can inhibit various steps in type I IFN production and response. Exogenous type I IFNs inhibit viral growth in vitro. In various animal species infected in vivo, type I IFN deficiencies underlie higher viral loads and more severe disease than in control animals. The early administration of exogenous type I IFNs improves infection control. In humans, inborn errors of, and auto-antibodies against type I IFNs underlie life-threatening COVID-19 pneumonia. Overall, type I IFNs are essential for host defense against SARS-CoV-2 in individual cells and whole organisms.
format Online
Article
Text
id pubmed-8786610
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-87866102022-01-25 Type I interferons and SARS-CoV-2: from cells to organisms Bastard, Paul Zhang, Qian Zhang, Shen-Ying Jouanguy, Emmanuelle Casanova, Jean-Laurent Curr Opin Immunol Article Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro produce low levels of type I IFNs, and SARS-CoV-2 proteins can inhibit various steps in type I IFN production and response. Exogenous type I IFNs inhibit viral growth in vitro. In various animal species infected in vivo, type I IFN deficiencies underlie higher viral loads and more severe disease than in control animals. The early administration of exogenous type I IFNs improves infection control. In humans, inborn errors of, and auto-antibodies against type I IFNs underlie life-threatening COVID-19 pneumonia. Overall, type I IFNs are essential for host defense against SARS-CoV-2 in individual cells and whole organisms. The Authors. Published by Elsevier Ltd. 2022-02 2022-01-25 /pmc/articles/PMC8786610/ /pubmed/35149239 http://dx.doi.org/10.1016/j.coi.2022.01.003 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Bastard, Paul
Zhang, Qian
Zhang, Shen-Ying
Jouanguy, Emmanuelle
Casanova, Jean-Laurent
Type I interferons and SARS-CoV-2: from cells to organisms
title Type I interferons and SARS-CoV-2: from cells to organisms
title_full Type I interferons and SARS-CoV-2: from cells to organisms
title_fullStr Type I interferons and SARS-CoV-2: from cells to organisms
title_full_unstemmed Type I interferons and SARS-CoV-2: from cells to organisms
title_short Type I interferons and SARS-CoV-2: from cells to organisms
title_sort type i interferons and sars-cov-2: from cells to organisms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786610/
https://www.ncbi.nlm.nih.gov/pubmed/35149239
http://dx.doi.org/10.1016/j.coi.2022.01.003
work_keys_str_mv AT bastardpaul typeiinterferonsandsarscov2fromcellstoorganisms
AT zhangqian typeiinterferonsandsarscov2fromcellstoorganisms
AT zhangshenying typeiinterferonsandsarscov2fromcellstoorganisms
AT jouanguyemmanuelle typeiinterferonsandsarscov2fromcellstoorganisms
AT casanovajeanlaurent typeiinterferonsandsarscov2fromcellstoorganisms

Ejemplares similares